- Home
- NXPL vs CYCN Comparison
NXPL vs CYCN Comparison
Compare NXPL & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NXPL | CYCN |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.3M | 16.6M |
| IPO Year | 2011 | 2019 |
Fundamental Metrics
Financial Performance| Metric | NXPL | CYCN |
|---|---|---|
| Price | $7.01 | $3.97 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 28.4K | 13.5K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.29 | 8.26 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,869,558.00 | $2,074,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 2.50 | ★ 3.70 |
| 52 Week Low | $0.34 | $1.03 |
| 52 Week High | $8.37 | $8.48 |
Technical Indicators
Market Signals| Indicator | NXPL | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 60.20 | 64.40 |
| Support Level | $5.54 | $2.93 |
| Resistance Level | $7.13 | $3.97 |
| Average True Range (ATR) | 0.40 | 0.22 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 78.57 | 75.88 |
Price Performance
Historical ComparisonAbout NXPL NextPlat Corp
NextPlat Corp is an e-commerce and healthcare company. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.